MOTS-c and longevity: why a mitochondrial peptide has researchers paying attention

The short version: a small peptide your mitochondria make, linked in mouse studies to how muscles handle fuel.

TL;DR

• MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA.
• In mouse studies, it improved metabolic flexibility and appeared to mimic some effects of exercise. That has not been shown in people.
• FDA removed MOTS-c from Category 2 on April 22, 2026. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list.

What it is

MOTS-c (in plain English: mitochondrial open reading frame of the 12S rRNA-c — a 16-amino-acid peptide encoded by a small piece of mitochondrial DNA) was discovered in 2015 by researchers at the University of Southern California (Lee et al., Cell Metab, 2015). It belongs to a family called mitochondrial-derived peptides (in plain English: tiny peptides made by the mitochondria themselves rather than the cell nucleus).

How it works

Think of mitochondria as the small power plants inside every cell. Researchers describe MOTS-c as a peptide they release that travels through the bloodstream like a hormone. In mouse studies, it signaled tissues — especially skeletal muscle — to use glucose more efficiently. In mouse studies, MOTS-c administration prevented age-related and diet-induced insulin resistance, as well as diet-induced weight gain (Lee et al., Cell Metab, 2015). In mice, the metabolic profile resembled what happens after exercise — which is why some researchers describe MOTS-c as an "exercise mimetic."

Who asks about it

People ask this when they have heard MOTS-c described in longevity podcasts and want to know what the research actually says. The honest answer: mouse data, some measurements of MOTS-c levels in people, and very limited human clinical trials so far.

What the research says

The original 2015 Cell Metabolism paper showed MOTS-c administration prevented age-related and diet-induced insulin resistance in mice. Subsequent work documented circulating MOTS-c levels declining with age in men (D'Souza et al., Aging, 2020) and rising in response to exercise in humans (Reynolds et al., Nat Commun, 2021). Human clinical trial data on exogenous MOTS-c administration remains limited compared to the animal literature. FDA removed MOTS-c from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, MOTS-c is not in any FDA 503A category and is not on the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding MOTS-c to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision.

What is still unknown

The published evidence is primarily preclinical. Whether MOTS-c has any benefit in people is not established, and FDA has not made a final decision on its compounding status.

The Halftime POV

MOTS-c is the kind of peptide that makes the longevity field exciting and frustrating in the same breath. The biology is novel. The data in humans is thin. We will not pretend animal data is human data.

Related reading:

• MOTS-c: the mitochondria-derived peptide in the literature
• MOTS-c: the mitochondria-derived peptide explained
• Category 1 vs Category 2 peptides: the access framework

FAQ

Q: What is MOTS-c? A: MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA, discovered in 2015. It appears to act as a hormone-like signal that influences metabolic flexibility, glucose handling, and exercise response in animal studies.

Q: Is MOTS-c a longevity peptide? A: MOTS-c is studied in the context of metabolic aging and exercise mimicry. It is not currently FDA-approved, and human clinical trial data is limited compared to the animal literature.

Q: What is MOTS-c's compounding status? A: FDA removed MOTS-c from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, MOTS-c is not in any FDA 503A category and is not on the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding MOTS-c to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision. This page is education only and does not cover sourcing.

Disclaimer

Several peptides discussed in this article — including MOTS-c — were previously in FDA's Category 2. FDA removed them from Category 2 on April 22, 2026. As of September 14, 2026, they are not in any FDA 503A category and are not on the 503A bulks list. This article is educational and is not medical advice.

Sources

• Lee C et al., Cell Metabolism, 2015 — The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis
• Reynolds JC et al., Nature Communications, 2021 — MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis
• D'Souza RF et al., Aging, 2020 — Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition

This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.